dulaglutide vs Liraglutide (Victoza)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

dulaglutide · Trulicity

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
Reliable signal

NCT01394952 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).

Next expected readout: April 2027 · NCT07537088 (registry estimate)

Reported efficacy

Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04) (met)

Result source: NCT03495102

Liraglutide (Victoza)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Reliable signal

NCT00318461 · Phase 3 · completed

This was a large (n=1091), randomized, double-blind, parallel-group trial with both a placebo-controlled comparison (liraglutide + metformin vs metformin + liraglutide placebo) and an active-controlled comparison (glimepiride + metformin). The primary endpoint was change in HbA1c at week 26, a hard, regulator-accepted outcome for type 2 diabetes. The prespecified primary comparisons for liraglutide 1.2 mg and 1.8 mg/day were met: both were significantly superior to metformin alone (p<0.0001) and non-inferior to glimepiride + metformin within the 0.4% margin. The 0.6 mg dose was superior to metformin but did not meet non-inferiority against glimepiride + metformin, which does not negate the positive results for the clinically relevant doses.

Next expected readout: June 2027 · NCT03883412 (registry estimate)

Reported efficacy

Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26); Change in Glycosylated A1c (HbA1c) at Week 104 (week 0, week 104): Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07) (met)

Result source: NCT00318461

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdulaglutideLiraglutide (Victoza)
HbA1c, change-2.0% vs -1.1%−0.9 vs placebo1.5 mg · wk 28 · n 133NCT04591626
25 other results
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 132 · Phase 3 · primary NCT02597049
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 130 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 134 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 131 · Phase 3 · primary NCT02597049
  • -1.4% vs -0.7% wk 28 · n 150 · Phase 3 · primary NCT02152371
  • -1.4% vs -0.1% wk 24 · n 215 · Phase 3 · primary NCT01769378
  • -1.2% vs -1.1% 1.5 mg · wk 26 · n 138 · Phase 3 · primary NCT01621178
  • -1.7% vs -1.2% 1.5 mg · wk 26 · n 253 · Phase 3 · primary NCT01648582
  • -1.5% vs -0.9% 1.5 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -1.4% 1.5 mg weekly · wk 26 · n 279 · Phase 3 · primary NCT01624259
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.3% vs -1.2% 0.75 mg · wk 26 · n 252 · Phase 3 · primary NCT01648582
  • -1.2% vs -0.9% 0.75 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -0.9% wk 26 · n 178 · Phase 3 · primary NCT01584232
  • -1% vs 0.5% 1.5 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.5% vs 0.5% 0.75 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.9% vs -1.7% 1.5 mg · wk 156 · n 6579 · Phase 3 · secondary NCT04255433
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.5% vs -0.9% 1.5 mg · wk 52 · n 253 · Phase 3 · secondary NCT01648582
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.0% vs -0.9% 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.4% vs -0.4% 4.5 mg · wk 18 · n 66 · Phase 2 · primary NCT02973100
  • -1.3% vs -0.4% 3.0 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.2% vs -0.4% 1.5 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.4% vs 0.1% wk 16 · n 120 · Phase 4 · primary NCT02750410
-0.6% vs 0.4%−1.1 vs placebo1.8 mg · wk 26 · n 66NCT01541215
27 other results
  • -1% vs -1.0% 1.8 mg daily · wk 26 · n 236 · Phase 3 · primary NCT00318461
  • -0.6% vs -0.5% 1.8 mg daily · wk 104 · n 235 · Phase 3 · primary NCT00318461
  • -1.0% vs -1.0% 1.2 mg daily · wk 26 · n 232 · Phase 3 · primary NCT00318461
  • -0.6% vs -0.5% 1.2 mg daily · wk 104 · n 231 · Phase 3 · primary NCT00318461
  • -0.7% vs -1.0% 0.6 mg daily · wk 26 · n 239 · Phase 3 · primary NCT00318461
  • -0.4% vs -0.5% 0.6 mg daily · wk 104 · n 239 · Phase 3 · primary NCT00318461
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 273 · Phase 3 · primary NCT02607306
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 151 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -0.7% vs 0.7% 1.8 mg · wk 52 · n 56 · Phase 3 · secondary NCT01541215
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 273 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • 7.9% vs 8.9% wk 26 · n 32 · Phase 4 · primary NCT01505673
  • 6.4% vs 6.4% wk 16 · n 15 · Phase 4 · primary NCT02765399
  • -1.1% vs -0.5% wk 26 · n 176 · Phase 4 · primary NCT01907854
  • -1.8% vs -1.2% wk 26 · n 194 · Phase 4 · primary NCT01973231
  • -1.7% vs -1.0% wk 26 · n 162 · Phase 4 · primary NCT02008682
  • 4.1% vs 3.4% wk 26 · n 46 · Phase 4 · primary NCT01966978
  • -1.4% vs -1.1% 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -1.3% vs -0.7% wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.1% vs 0.2% liraglutide 1.2/1.8mg · wk 26 · Phase 3 · primary NCT00318422
Body weight, change (kg)-0.8 vs 0.4−1.2 vs placebo1.5 mg · wk 28 · n 133NCT04591626
18 other results
  • -1.9 vs 0.5 wk 28 · n 150 · Phase 3 · secondary NCT02152371
  • -0.9 vs -0.2 wk 24 · n 212 · Phase 3 · secondary NCT01769378
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.1 vs 1.4 1.5 mg · wk 52 · n 258 · Phase 3 · secondary NCT01648582
  • -2.8 vs 1.1 1.5 mg · wk 26 · n 140 · Phase 3 · secondary NCT01621178
  • -1.5 vs 1.0 1.5 mg · wk 26 · n 258 · Phase 3 · secondary NCT01648582
  • -1.5 vs 0.9 1.5 mg · wk 26 · n 222 · Phase 3 · secondary NCT01644500
  • -2.9 vs -3.6 1.5 mg weekly · wk 26 · n 299 · Phase 3 · secondary NCT01624259
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • -0.8 vs 1.4 0.75 mg · wk 52 · n 257 · Phase 3 · secondary NCT01648582
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • -0.9 vs 1.0 0.75 mg · wk 26 · n 257 · Phase 3 · secondary NCT01648582
  • -0.8 vs 0.9 0.75 mg · wk 26 · n 224 · Phase 3 · secondary NCT01644500
  • -0.5 vs 0.9 wk 26 · n 180 · Phase 3 · secondary NCT01584232
  • -4.1 vs -1.6 4.5 mg · wk 18 · n 67 · Phase 2 · secondary NCT02973100
  • -3.9 vs -1.6 3.0 mg · wk 18 · n 74 · Phase 2 · secondary NCT02973100
  • -2.8 vs -1.6 1.5 mg · wk 18 · n 72 · Phase 2 · secondary NCT02973100
  • -0.2 vs -0.3 wk 16 · n 120 · Phase 4 · secondary NCT02750410
-2.3 vs 1.0−3.3 vs placebo1.8 mg · wk 52 · n 56NCT01541215
22 other results
  • -2.5 vs -0.9 1.8 mg · wk 26 · n 60 · Phase 3 · secondary NCT01541215
  • -2.8 vs 0.9 1.8 mg daily · wk 26 · n 241 · Phase 3 · secondary NCT00318461
  • -2.9 vs 0.7 1.8 mg daily · wk 104 · n 241 · Phase 3 · secondary NCT00318461
  • -2.6 vs 0.9 1.2 mg daily · wk 26 · n 236 · Phase 3 · secondary NCT00318461
  • -3.0 vs 0.7 1.2 mg daily · wk 104 · n 236 · Phase 3 · secondary NCT00318461
  • -1.8 vs 0.9 0.6 mg daily · wk 26 · n 242 · Phase 3 · secondary NCT00318461
  • -2.1 vs 0.7 0.6 mg daily · wk 104 · n 242 · Phase 3 · secondary NCT00318461
  • 2.9 vs 4.1 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1 vs 4.1 wk 52 · n 273 · Phase 3 · secondary NCT02607306
  • 0.2 vs 1.3 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -2.5 vs 1.3 wk 26 · n 151 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • 1.2 vs 3 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • -3.8 vs -3.5 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -3.3 vs -1.8 wk 26 · n 192 · Phase 4 · secondary NCT01907854
  • -4.2 vs -3.7 wk 26 · n 194 · Phase 4 · secondary NCT01973231
  • -5.4 vs -1.5 wk 4 · n 165 · Phase 4 · secondary NCT01917656
  • -0.6 vs 3.1 wk 26 · n 46 · Phase 4 · secondary NCT01966978
HbA1c below 7%75.9% vs 33.8%+42.1 vs placebo1.5 mg · wk 28 · n 133NCT04591626
8 other results
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 32.9% vs 29.1% 1.5 mg · wk 52 · n 152 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 68.2% vs 20% 4.5 mg · wk 18 · n 66 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 3.0 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 1.5 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 0% vs 47.4% wk 16 · n 116 · Phase 4 · secondary NCT02750410
63.7% vs 36.5%+27.2 vs placebo1.8 mg · wk 26 · n 66NCT01541215
3 other results
  • 51.8% vs 23.2% wk 26 · n 195 · Phase 3 · secondary NCT02964247
  • 76.5% vs 52.6% wk 26 · n 162 · Phase 4 · secondary NCT02008682
  • 44% vs 20% wk 26 · n 46 · Phase 4 · secondary NCT01966978
Fasting plasma glucose, change-2.2 vs -2.4vs Insulin Glargine1.5 mg · wk 52 · n 253NCT01648582
3 other results
  • -2.4 vs -2.6 1.5 mg · wk 26 · n 253 · Phase 3 · secondary NCT01648582
  • -1.5 vs -2.4 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.7 vs -2.6 0.75 mg · wk 26 · n 252 · Phase 3 · secondary NCT01648582
-1.6 vs 1.0−2.6 vs placebo1.8 mg · wk 52 · n 56NCT01541215
21 other results
  • -1.1 vs 0.8 1.8 mg · wk 26 · n 66 · Phase 3 · secondary NCT01541215
  • -1.7 vs -1.3 1.8 mg daily · wk 26 · n 235 · Phase 3 · secondary NCT00318461
  • -1.2 vs -0.6 1.8 mg daily · wk 104 · n 234 · Phase 3 · secondary NCT00318461
  • -1.6 vs -1.3 1.2 mg daily · wk 26 · n 234 · Phase 3 · secondary NCT00318461
  • -1.2 vs -0.6 1.2 mg daily · wk 104 · n 233 · Phase 3 · secondary NCT00318461
  • -1.1 vs -1.3 0.6 mg daily · wk 26 · n 238 · Phase 3 · secondary NCT00318461
  • -0.8 vs -0.6 0.6 mg daily · wk 104 · n 238 · Phase 3 · secondary NCT00318461
  • -4.1 vs -4.0 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -2.6 vs -4.0 wk 52 · n 272 · Phase 3 · secondary NCT02607306
  • -3.6 vs -3.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -3.9 vs -3.7 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -1.9 vs -3.5 wk 26 · n 150 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 6.4 vs 6.4 wk 16 · n 15 · Phase 4 · primary NCT02765399
  • -2.2 vs -1.2 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -2.9 vs -1.6 wk 26 · n 194 · Phase 4 · secondary NCT01973231
  • -2.3 vs -1.2 wk 26 · n 168 · Phase 4 · secondary NCT02008682
  • -0.1 vs 0.1 wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.8 vs -0.6 wk 4 · n 143 · Phase 4 · secondary NCT01917656
3-point MACE (% with event)12% vs 13.4%−1.4 vs placebon 4949NCT01394952
1 other result
  • 13.1% vs 12.2% 1.5 mg · wk 259 · n 6579 · Phase 3 · primary NCT04255433
13% vs 14.9%−1.9 vs placebowk 260 · n 4668NCT01179048

HbA1c, change

dulaglutide
-2.0% vs -1.1%−0.9 vs placebo1.5 mg · wk 28 · n 133NCT04591626
25 other results
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 132 · Phase 3 · primary NCT02597049
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 130 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 134 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 131 · Phase 3 · primary NCT02597049
  • -1.4% vs -0.7% wk 28 · n 150 · Phase 3 · primary NCT02152371
  • -1.4% vs -0.1% wk 24 · n 215 · Phase 3 · primary NCT01769378
  • -1.2% vs -1.1% 1.5 mg · wk 26 · n 138 · Phase 3 · primary NCT01621178
  • -1.7% vs -1.2% 1.5 mg · wk 26 · n 253 · Phase 3 · primary NCT01648582
  • -1.5% vs -0.9% 1.5 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -1.4% 1.5 mg weekly · wk 26 · n 279 · Phase 3 · primary NCT01624259
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.3% vs -1.2% 0.75 mg · wk 26 · n 252 · Phase 3 · primary NCT01648582
  • -1.2% vs -0.9% 0.75 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -0.9% wk 26 · n 178 · Phase 3 · primary NCT01584232
  • -1% vs 0.5% 1.5 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.5% vs 0.5% 0.75 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.9% vs -1.7% 1.5 mg · wk 156 · n 6579 · Phase 3 · secondary NCT04255433
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.5% vs -0.9% 1.5 mg · wk 52 · n 253 · Phase 3 · secondary NCT01648582
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.0% vs -0.9% 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.4% vs -0.4% 4.5 mg · wk 18 · n 66 · Phase 2 · primary NCT02973100
  • -1.3% vs -0.4% 3.0 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.2% vs -0.4% 1.5 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.4% vs 0.1% wk 16 · n 120 · Phase 4 · primary NCT02750410
Liraglutide (Victoza)
-0.6% vs 0.4%−1.1 vs placebo1.8 mg · wk 26 · n 66NCT01541215
27 other results
  • -1% vs -1.0% 1.8 mg daily · wk 26 · n 236 · Phase 3 · primary NCT00318461
  • -0.6% vs -0.5% 1.8 mg daily · wk 104 · n 235 · Phase 3 · primary NCT00318461
  • -1.0% vs -1.0% 1.2 mg daily · wk 26 · n 232 · Phase 3 · primary NCT00318461
  • -0.6% vs -0.5% 1.2 mg daily · wk 104 · n 231 · Phase 3 · primary NCT00318461
  • -0.7% vs -1.0% 0.6 mg daily · wk 26 · n 239 · Phase 3 · primary NCT00318461
  • -0.4% vs -0.5% 0.6 mg daily · wk 104 · n 239 · Phase 3 · primary NCT00318461
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 273 · Phase 3 · primary NCT02607306
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 151 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -0.7% vs 0.7% 1.8 mg · wk 52 · n 56 · Phase 3 · secondary NCT01541215
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 273 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • 7.9% vs 8.9% wk 26 · n 32 · Phase 4 · primary NCT01505673
  • 6.4% vs 6.4% wk 16 · n 15 · Phase 4 · primary NCT02765399
  • -1.1% vs -0.5% wk 26 · n 176 · Phase 4 · primary NCT01907854
  • -1.8% vs -1.2% wk 26 · n 194 · Phase 4 · primary NCT01973231
  • -1.7% vs -1.0% wk 26 · n 162 · Phase 4 · primary NCT02008682
  • 4.1% vs 3.4% wk 26 · n 46 · Phase 4 · primary NCT01966978
  • -1.4% vs -1.1% 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -1.3% vs -0.7% wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.1% vs 0.2% liraglutide 1.2/1.8mg · wk 26 · Phase 3 · primary NCT00318422

Body weight, change (kg)

dulaglutide
-0.8 vs 0.4−1.2 vs placebo1.5 mg · wk 28 · n 133NCT04591626
18 other results
  • -1.9 vs 0.5 wk 28 · n 150 · Phase 3 · secondary NCT02152371
  • -0.9 vs -0.2 wk 24 · n 212 · Phase 3 · secondary NCT01769378
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.1 vs 1.4 1.5 mg · wk 52 · n 258 · Phase 3 · secondary NCT01648582
  • -2.8 vs 1.1 1.5 mg · wk 26 · n 140 · Phase 3 · secondary NCT01621178
  • -1.5 vs 1.0 1.5 mg · wk 26 · n 258 · Phase 3 · secondary NCT01648582
  • -1.5 vs 0.9 1.5 mg · wk 26 · n 222 · Phase 3 · secondary NCT01644500
  • -2.9 vs -3.6 1.5 mg weekly · wk 26 · n 299 · Phase 3 · secondary NCT01624259
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • -0.8 vs 1.4 0.75 mg · wk 52 · n 257 · Phase 3 · secondary NCT01648582
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • -0.9 vs 1.0 0.75 mg · wk 26 · n 257 · Phase 3 · secondary NCT01648582
  • -0.8 vs 0.9 0.75 mg · wk 26 · n 224 · Phase 3 · secondary NCT01644500
  • -0.5 vs 0.9 wk 26 · n 180 · Phase 3 · secondary NCT01584232
  • -4.1 vs -1.6 4.5 mg · wk 18 · n 67 · Phase 2 · secondary NCT02973100
  • -3.9 vs -1.6 3.0 mg · wk 18 · n 74 · Phase 2 · secondary NCT02973100
  • -2.8 vs -1.6 1.5 mg · wk 18 · n 72 · Phase 2 · secondary NCT02973100
  • -0.2 vs -0.3 wk 16 · n 120 · Phase 4 · secondary NCT02750410
Liraglutide (Victoza)
-2.3 vs 1.0−3.3 vs placebo1.8 mg · wk 52 · n 56NCT01541215
22 other results
  • -2.5 vs -0.9 1.8 mg · wk 26 · n 60 · Phase 3 · secondary NCT01541215
  • -2.8 vs 0.9 1.8 mg daily · wk 26 · n 241 · Phase 3 · secondary NCT00318461
  • -2.9 vs 0.7 1.8 mg daily · wk 104 · n 241 · Phase 3 · secondary NCT00318461
  • -2.6 vs 0.9 1.2 mg daily · wk 26 · n 236 · Phase 3 · secondary NCT00318461
  • -3.0 vs 0.7 1.2 mg daily · wk 104 · n 236 · Phase 3 · secondary NCT00318461
  • -1.8 vs 0.9 0.6 mg daily · wk 26 · n 242 · Phase 3 · secondary NCT00318461
  • -2.1 vs 0.7 0.6 mg daily · wk 104 · n 242 · Phase 3 · secondary NCT00318461
  • 2.9 vs 4.1 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1 vs 4.1 wk 52 · n 273 · Phase 3 · secondary NCT02607306
  • 0.2 vs 1.3 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -2.5 vs 1.3 wk 26 · n 151 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • 1.2 vs 3 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • -3.8 vs -3.5 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -3.3 vs -1.8 wk 26 · n 192 · Phase 4 · secondary NCT01907854
  • -4.2 vs -3.7 wk 26 · n 194 · Phase 4 · secondary NCT01973231
  • -5.4 vs -1.5 wk 4 · n 165 · Phase 4 · secondary NCT01917656
  • -0.6 vs 3.1 wk 26 · n 46 · Phase 4 · secondary NCT01966978

HbA1c below 7%

dulaglutide
75.9% vs 33.8%+42.1 vs placebo1.5 mg · wk 28 · n 133NCT04591626
8 other results
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 32.9% vs 29.1% 1.5 mg · wk 52 · n 152 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 68.2% vs 20% 4.5 mg · wk 18 · n 66 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 3.0 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 1.5 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 0% vs 47.4% wk 16 · n 116 · Phase 4 · secondary NCT02750410
Liraglutide (Victoza)
63.7% vs 36.5%+27.2 vs placebo1.8 mg · wk 26 · n 66NCT01541215
3 other results
  • 51.8% vs 23.2% wk 26 · n 195 · Phase 3 · secondary NCT02964247
  • 76.5% vs 52.6% wk 26 · n 162 · Phase 4 · secondary NCT02008682
  • 44% vs 20% wk 26 · n 46 · Phase 4 · secondary NCT01966978

Fasting plasma glucose, change

dulaglutide
-2.2 vs -2.4vs Insulin Glargine1.5 mg · wk 52 · n 253NCT01648582
3 other results
  • -2.4 vs -2.6 1.5 mg · wk 26 · n 253 · Phase 3 · secondary NCT01648582
  • -1.5 vs -2.4 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.7 vs -2.6 0.75 mg · wk 26 · n 252 · Phase 3 · secondary NCT01648582
Liraglutide (Victoza)
-1.6 vs 1.0−2.6 vs placebo1.8 mg · wk 52 · n 56NCT01541215
21 other results
  • -1.1 vs 0.8 1.8 mg · wk 26 · n 66 · Phase 3 · secondary NCT01541215
  • -1.7 vs -1.3 1.8 mg daily · wk 26 · n 235 · Phase 3 · secondary NCT00318461
  • -1.2 vs -0.6 1.8 mg daily · wk 104 · n 234 · Phase 3 · secondary NCT00318461
  • -1.6 vs -1.3 1.2 mg daily · wk 26 · n 234 · Phase 3 · secondary NCT00318461
  • -1.2 vs -0.6 1.2 mg daily · wk 104 · n 233 · Phase 3 · secondary NCT00318461
  • -1.1 vs -1.3 0.6 mg daily · wk 26 · n 238 · Phase 3 · secondary NCT00318461
  • -0.8 vs -0.6 0.6 mg daily · wk 104 · n 238 · Phase 3 · secondary NCT00318461
  • -4.1 vs -4.0 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -2.6 vs -4.0 wk 52 · n 272 · Phase 3 · secondary NCT02607306
  • -3.6 vs -3.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -3.9 vs -3.7 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -1.9 vs -3.5 wk 26 · n 150 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 6.4 vs 6.4 wk 16 · n 15 · Phase 4 · primary NCT02765399
  • -2.2 vs -1.2 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -2.9 vs -1.6 wk 26 · n 194 · Phase 4 · secondary NCT01973231
  • -2.3 vs -1.2 wk 26 · n 168 · Phase 4 · secondary NCT02008682
  • -0.1 vs 0.1 wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.8 vs -0.6 wk 4 · n 143 · Phase 4 · secondary NCT01917656

3-point MACE (% with event)

dulaglutide
12% vs 13.4%−1.4 vs placebon 4949NCT01394952
1 other result
  • 13.1% vs 12.2% 1.5 mg · wk 259 · n 6579 · Phase 3 · primary NCT04255433
Liraglutide (Victoza)
13% vs 14.9%−1.9 vs placebowk 260 · n 4668NCT01179048
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety

Coverage. dulaglutide: 11 of 11 rows · Liraglutide (Victoza): 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricdulaglutide
Rows use multiple source trials
Liraglutide (Victoza)
Rows use multiple source trials
BMI
absolute change · kg
-0.1 vs 0 placebo kg @ 26wk1.5 mga,b,c
NCT02963766 · Phase 3
show 1 more dose
-0.2 vs 0 placebo kg @ 26wk0.75 mg
NCT02963766 · Phase 3
-1.02 vs -0.72 placebo kg @ 26wkb,c
NCT02964247 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose Change mg/dL
absolute change · mg
-34.81 vs -34.25 Liraglutide mg @ 26wk1.5 mg weeklyb,c
NCT01624259 · Phase 3 · registry result, not featured evidence
-27 vs -11.97 placebo mg @ 26wkb,c
NCT02964247 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
No placebo or comparator arm
-1.5% (n=383) @ 52wk1.5 mga,b,c,d
NCT04809220 · Phase 3 · registry result, not featured evidence
show 1 more dose
-1.19% (n=193) @ 52wk0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
-2.02% (n=200) @ 32wka,b,c,d
NCT02298192 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.01% (n=189) @ 32wk
NCT02298192 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain
responder rate · % of participants
51.8% (n=139) vs 21.1% (n=147) placebo @ 28wk1.5 mge,b,c,f
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
47.69% (n=195) vs 19.15% (n=94) placebo @ 26wke,b,c,f
Yes
NCT02964247 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7 Without Weight Gain
responder rate · % of participants
51.8% (n=139) vs 21.1% (n=147) placebo @ 28wk1.5 mge,b,c,f
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
47.69% (n=195) vs 19.15% (n=94) placebo @ 26wke,b,c,f
Yes
NCT02964247 · Phase 3 · registry result, not featured evidence
Postprandial Glucose AUC
absolute change · mg
-238.46 vs 15.56 placebo mg @ 4wkg,b,c,h
NCT03315780 · Phase 4 · registry result, not featured evidence
5678 vs 5557 placebo mgg,b,c,h
NCT01937598 · Phase 3 · registry result, not featured evidence
Weight
percent change · % of baseline
-4.82% (n=6578) vs -11.6% (n=6586) Tirzepatide @ 156wk1.5 mgb,c,i
NCT04255433 · Phase 3 · registry result, not featured evidence
-7.2% (n=35) vs -3.1% (n=37) placebo @ 84wkb,c,i
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
Dropout rate
0.3%j
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 45 more results
4.4%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.8%4.5 mg
NCT03495102 · Phase 3
10.9%3 mg
NCT03495102 · Phase 3
9.2%1.5 mg
NCT03495102 · Phase 3
—1.5 mg
NCT01621178 · Phase 3
—0.75 mg
NCT01621178 · Phase 3
3.8%1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
3.9%0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—1.5 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
2.5%Dulaglutide
NCT02750410 · Phase 4 · registry result, not featured evidence
—
NCT03315780 · Phase 4 · registry result, not featured evidence
2.2%1.5 mg
NCT04255433 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
3.1%0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
4.9%1.5 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
3.5%0.75 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
8%
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
12.4%1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
14.8%0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
10.4%
NCT01769378 · Phase 3 · registry result, not featured evidence
9%1.5 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
9.7%0.75 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
—1.5 mg weekly
NCT01624259 · Phase 3 · registry result, not featured evidence
10%LY2189265
NCT01624259 · Phase 3 · registry result, not featured evidence
9.2%4.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
5.1%3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide + Warfarin
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide Alone
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
16.7%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
21.1%1.8 mg dailyk
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
18.3%1.2 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
14%0.6 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
3%
NCT01179048 · Phase 3
15.2%1.8 mg
NCT01541215 · Phase 3
—1.8 mg
NCT01541215 · Phase 3
—1.8 mg
NCT01541215 · Phase 3
0%
NCT03260881 · Phase 4 · registry result, not featured evidence
41.2%
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
55.2%1.8 mg
NCT02730377 · Phase 4 · registry result, not featured evidence
6.3%
NCT02765399 · Phase 4 · registry result, not featured evidence
22%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
10.9%
NCT02014740 · Phase 4 · registry result, not featured evidence
0%
NCT02299388 · Phase 4 · registry result, not featured evidence
8.6%
NCT01505673 · Phase 4 · registry result, not featured evidence
7.9%
NCT01907854 · Phase 4 · registry result, not featured evidence
5.4%
NCT01973231 · Phase 4 · registry result, not featured evidence
14.7%
NCT02008682 · Phase 4 · registry result, not featured evidence
15.1%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
—
NCT02889510 · Phase 3 · registry result, not featured evidence
5.5%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
16.1%Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
55.1%
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
4%
NCT03175120 · Phase 3 · registry result, not featured evidence
4.3%
NCT02501161 · Phase 3 · registry result, not featured evidence
1.5%
NCT02964247 · Phase 3 · registry result, not featured evidence
7.6%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
3.7%Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
0%
NCT02911948 · Phase 3 · registry result, not featured evidence
4.8%
NCT02773368 · Phase 3 · registry result, not featured evidence
0.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
2.9%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
—
NCT01937598 · Phase 3 · registry result, not featured evidence
10.1%
NCT01952145 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—j
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 45 more results
1.7%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.6%4.5 mg
NCT03495102 · Phase 3
1.1%3 mg
NCT03495102 · Phase 3
0.8%1.5 mg
NCT03495102 · Phase 3
—1.5 mg
NCT01621178 · Phase 3
—0.75 mg
NCT01621178 · Phase 3
1.9%1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
0%0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—1.5 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
1.7%Dulaglutide
NCT02750410 · Phase 4 · registry result, not featured evidence
—
NCT03315780 · Phase 4 · registry result, not featured evidence
—1.5 mg
NCT04255433 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
0%0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
1.4%1.5 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
0%0.75 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
4%
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
2.3%1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
4.3%0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
4.2%
NCT01769378 · Phase 3 · registry result, not featured evidence
2.5%1.5 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
0.4%0.75 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
—1.5 mg weekly
NCT01624259 · Phase 3 · registry result, not featured evidence
6%LY2189265
NCT01624259 · Phase 3 · registry result, not featured evidence
2.6%4.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
1.3%3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide + Warfarin
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide Alone
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
8.3%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
12%1.8 mg dailyk
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
9.5%1.2 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.5%0.6 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT01179048 · Phase 3
0%1.8 mg
NCT01541215 · Phase 3
—1.8 mg
NCT01541215 · Phase 3
—1.8 mg
NCT01541215 · Phase 3
—
NCT03260881 · Phase 4 · registry result, not featured evidence
7.4%
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
7.9%1.8 mg
NCT02730377 · Phase 4 · registry result, not featured evidence
—
NCT02765399 · Phase 4 · registry result, not featured evidence
—
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
—
NCT02014740 · Phase 4 · registry result, not featured evidence
—
NCT02299388 · Phase 4 · registry result, not featured evidence
—
NCT01505673 · Phase 4 · registry result, not featured evidence
—
NCT01907854 · Phase 4 · registry result, not featured evidence
—
NCT01973231 · Phase 4 · registry result, not featured evidence
—
NCT02008682 · Phase 4 · registry result, not featured evidence
6.4%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
—
NCT02889510 · Phase 3 · registry result, not featured evidence
1.4%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
8.3%Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
—
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
0.7%
NCT03175120 · Phase 3 · registry result, not featured evidence
0.4%
NCT02501161 · Phase 3 · registry result, not featured evidence
—
NCT02964247 · Phase 3 · registry result, not featured evidence
2.9%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
2.2%Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
—
NCT02911948 · Phase 3 · registry result, not featured evidence
—
NCT02773368 · Phase 3 · registry result, not featured evidence
0.4%
NCT02420262 · Phase 3 · registry result, not featured evidence
1%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
2.9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
—
NCT01937598 · Phase 3 · registry result, not featured evidence
3.2%
NCT01952145 · Phase 3 · registry result, not featured evidence
Serious AEs
40.3%j
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 45 more results
5%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.2%4.5 mg
NCT03495102 · Phase 3
7.3%3 mg
NCT03495102 · Phase 3
8.7%1.5 mg
NCT03495102 · Phase 3
21.4%1.5 mg
NCT01621178 · Phase 3
25.3%0.75 mg
NCT01621178 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
1.9%1.5 mg
NCT02963766 · Phase 3
4%1.5 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
2%0.75 mg
NCT02963766 · Phase 3
2%0.75 mg
NCT02963766 · Phase 3
0%1.5 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
0%0.75 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
2.5%0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
5%0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
—Dulaglutide
NCT02750410 · Phase 4 · registry result, not featured evidence
0%
NCT03315780 · Phase 4 · registry result, not featured evidence
31.9%1.5 mg
NCT04255433 · Phase 3 · registry result, not featured evidence
3.8%1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
3.6%0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
5.6%1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
3.5%1.5 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
2.1%0.75 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
6%
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
9.3%1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
5.8%0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
3.8%
NCT01769378 · Phase 3 · registry result, not featured evidence
2.5%1.5 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
1.6%0.75 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
1.7%1.5 mg weekly
NCT01624259 · Phase 3 · registry result, not featured evidence
—LY2189265
NCT01624259 · Phase 3 · registry result, not featured evidence
3.9%4.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
8.9%3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
3.7%1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
0%1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
9.1%0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
0%Dulaglutide + Warfarin
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
0%Dulaglutide Alone
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
0%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
6.6%1.8 mg dailyk
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
10.4%1.2 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
14.9%0.6 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
49.7%
NCT01179048 · Phase 3
13.6%1.8 mg
NCT01541215 · Phase 3
13.5%1.8 mg
NCT01541215 · Phase 3
4.2%1.8 mg
NCT01541215 · Phase 3
0%
NCT03260881 · Phase 4 · registry result, not featured evidence
38.2%
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
9.4%1.8 mg
NCT02730377 · Phase 4 · registry result, not featured evidence
0%
NCT02765399 · Phase 4 · registry result, not featured evidence
11.1%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02014740 · Phase 4 · registry result, not featured evidence
0%
NCT02299388 · Phase 4 · registry result, not featured evidence
2.9%
NCT01505673 · Phase 4 · registry result, not featured evidence
3%
NCT01907854 · Phase 4 · registry result, not featured evidence
5.9%
NCT01973231 · Phase 4 · registry result, not featured evidence
1.6%
NCT02008682 · Phase 4 · registry result, not featured evidence
1.3%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02889510 · Phase 3 · registry result, not featured evidence
3.9%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
7.8%Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
0%
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
4.3%
NCT03175120 · Phase 3 · registry result, not featured evidence
11.9%
NCT02501161 · Phase 3 · registry result, not featured evidence
2.5%
NCT02964247 · Phase 3 · registry result, not featured evidence
6.2%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
5.1%Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
2.9%
NCT02911948 · Phase 3 · registry result, not featured evidence
2.9%
NCT02773368 · Phase 3 · registry result, not featured evidence
4.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
6.7%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
3.3%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
0%
NCT01937598 · Phase 3 · registry result, not featured evidence
1.8%
NCT01952145 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
j
nausea 14.9% (placebo 5.4%)
diarrhoea 13.5% (placebo 8.8%)
nasopharyngitis 11.4% (placebo 10.8%)
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 41 more results
nasopharyngitis 27.1%
diarrhoea 12.2%
nausea 9.4%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.5 mg
nausea 17.3%
diarrhoea 11.4%
vomiting 10.4%
NCT03495102 · Phase 3
3 mg
nausea 16.1%
diarrhoea 12.2%
vomiting 9.3%
NCT03495102 · Phase 3
1.5 mg
nausea 14.2%
diarrhoea 7.8%
vomiting 6.5%
NCT03495102 · Phase 3
1.5 mg
blood creatinine increased 38.5%
nausea 19.8%
diarrhoea 16.1%
NCT01621178 · Phase 3
0.75 mg
blood creatinine increased 37.4%
diarrhoea 15.8%
nausea 14.2%
NCT01621178 · Phase 3
1.5 mg
diarrhoea 21.2% (placebo 13.7%)
headache 15.4% (placebo 9.8%)
nausea 15.4% (placebo 7.8%)
NCT02963766 · Phase 3
1.5 mg
diarrhoea 12% (placebo 13.7%)
nausea 12% (placebo 7.8%)
abdominal pain upper 10% (placebo 7.8%)
NCT02963766 · Phase 3
0.75 mg
vomiting 17.6% (placebo 3.9%)
diarrhoea 15.7% (placebo 13.7%)
headache 13.7% (placebo 9.8%)
NCT02963766 · Phase 3
0.75 mg
headache 10.2% (placebo 9.8%)
vomiting 8.2% (placebo 3.9%)
abdominal pain 6.1% (placebo 5.9%)
NCT02963766 · Phase 3
1.5 mg
gastritis 14.3%
dyslipidaemia 9.5%
nausea 9.5%
NCT05659537 · Phase 4 · registry result, not featured evidence
0.75 mg
anaemia 21.4%
gastritis 14.3%
dyslipidaemia 7.1%
NCT05659537 · Phase 4 · registry result, not featured evidence
0.75 mg
nasopharyngitis 15.8% (placebo 30.8%)
abdominal discomfort 8.3% (placebo 12.8%)
constipation 6.7% (placebo 12.8%)
NCT02750410 · Phase 4 · registry result, not featured evidence
0.75 mg
nasopharyngitis 28.3% (placebo 30.8%)
constipation 10.8% (placebo 12.8%)
abdominal discomfort 9.2% (placebo 12.8%)
NCT02750410 · Phase 4 · registry result, not featured evidence
influenza 16.7% (placebo 0%)
decreased appetite 8.3% (placebo 0%)
diarrhoea 8.3% (placebo 8.3%)
NCT03315780 · Phase 4 · registry result, not featured evidence
1.5 mg
nausea 22.3%
diarrhoea 18.9%
covid-19 15.1%
NCT04255433 · Phase 3 · registry result, not featured evidence
1.5 mg
constipation 12.5%
diarrhoea 10.2%
pyrexia 10%
NCT04809220 · Phase 3 · registry result, not featured evidence
0.75 mg
constipation 8.7%
nasopharyngitis 8.7%
covid-19 8.2%
NCT04809220 · Phase 3 · registry result, not featured evidence
1.5 mg
decreased appetite 22.2% (placebo 4.1%)
diabetic nephropathy 13.9% (placebo 15%)
diarrhoea 13.2% (placebo 8.2%)
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
1.5 mg
nausea 14.8% (placebo 3.6%)
back pain 9.2% (placebo 7.1%)
viral upper respiratory tract infection 6.3% (placebo 7.9%)
NCT02597049 · Phase 3 · registry result, not featured evidence
0.75 mg
diarrhoea 9.9% (placebo 2.9%)
back pain 8.5% (placebo 7.1%)
viral upper respiratory tract infection 5.7% (placebo 7.9%)
NCT02597049 · Phase 3 · registry result, not featured evidence
nausea 12% (placebo 1.3%)
diarrhoea 11.3% (placebo 4%)
upper respiratory tract infection 7.3% (placebo 6.7%)
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
1.5 mg
hyperlipidaemia 17.8%
diarrhoea 16.7%
lipase increased 10.5%
NCT01648582 · Phase 3 · registry result, not featured evidence
0.75 mg
hyperlipidaemia 19.5%
diarrhoea 10.9%
hypertension 10.9%
NCT01648582 · Phase 3 · registry result, not featured evidence
nausea 10.5% (placebo 0%)
diarrhoea 8.4% (placebo 0%)
eructation 5.9% (placebo 0%)
NCT01769378 · Phase 3 · registry result, not featured evidence
1.5 mg
diarrhoea 17.2%
hyperlipidaemia 11.1%
nausea 10.2%
NCT01644500 · Phase 3 · registry result, not featured evidence
0.75 mg
hyperlipidaemia 12.1%
diarrhoea 7.3%
lipase increased 5.6%
NCT01644500 · Phase 3 · registry result, not featured evidence
1.5 mg weekly
nausea 20.4%
diarrhoea 12%
dyspepsia 8%
NCT01624259 · Phase 3 · registry result, not featured evidence
4.5 mg
nausea 30.3% (placebo 4.9%)
diarrhoea 21.1% (placebo 11.1%)
vomiting 13.2% (placebo 4.9%)
NCT02973100 · Phase 2 · registry result, not featured evidence
3.0 mg
nausea 25.3% (placebo 4.9%)
diarrhoea 22.8% (placebo 11.1%)
decreased appetite 16.5% (placebo 1.2%)
NCT02973100 · Phase 2 · registry result, not featured evidence
1.5 mg
nausea 22.2% (placebo 4.9%)
diarrhoea 11.1% (placebo 11.1%)
vomiting 11.1% (placebo 4.9%)
NCT02973100 · Phase 2 · registry result, not featured evidence
1.5 mg
decreased appetite 18.2% (placebo 0%)
abdominal discomfort 9.1% (placebo 6.3%)
blood pressure decreased 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
1.5 mg
abdominal discomfort 10% (placebo 6.3%)
decreased appetite 10% (placebo 0%)
nausea 10% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.75 mg
abdominal discomfort 9.1% (placebo 6.3%)
nausea 9.1% (placebo 0%)
vomiting 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.75 mg
decreased appetite 18.2% (placebo 0%)
abdominal discomfort 9.1% (placebo 6.3%)
abdominal distension 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.5 mg
abdominal discomfort 0% (placebo 6.3%)
abdominal distension 0% (placebo 0%)
abdominal pain 0% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.5 mg
decreased appetite 18.2% (placebo 0%)
abdominal discomfort 9.1% (placebo 6.3%)
abdominal pain 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
headache 41.2%
nausea 41.2%
vomiting 35.3%
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
diarrhoea 8%
haemorrhoids 4%
injection site pain 4%
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
vomiting 11.5%
decreased appetite 7.7%
headache 7.7%
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
gastrooesophageal reflux disease 33.3%
atrioventricular block first degree 28.6%
headache 28.6%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
1.8 mg dailyk
nausea 21.5%
diarrhoea 16.5%
nasopharyngitis 14.9%
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 32 more results
1.2 mg daily
nausea 17.5%
nasopharyngitis 15%
headache 14.2%
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.6 mg daily
nasopharyngitis 17.8%
diarrhoea 12.8%
nausea 12.4%
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
nausea 11.1% (placebo 2.8%)
diarrhoea 5.7% (placebo 2.2%)
NCT01179048 · Phase 3
1.8 mg
nausea 28.8% (placebo 13.2%)
vomiting 25.8% (placebo 8.8%)
diarrhoea 22.7% (placebo 16.2%)
NCT01541215 · Phase 3
1.8 mg
nasopharyngitis 3.8% (placebo 27.9%)
vomiting 3.8% (placebo 8.8%)
abdominal pain 1.9% (placebo 7.4%)
NCT01541215 · Phase 3
1.8 mg
hyperglycaemia 2.1% (placebo 5.9%)
pharyngitis 2.1% (placebo 5.9%)
abdominal pain 0% (placebo 7.4%)
NCT01541215 · Phase 3
abdominal distention 31.6%
nausea 31.6%
NCT03260881 · Phase 4 · registry result, not featured evidence
1.8 mg
nausea 6.6%
NCT02730377 · Phase 4 · registry result, not featured evidence
nausea 25% (placebo 14.3%)
NCT02765399 · Phase 4 · registry result, not featured evidence
gi 77.8%
headache 25.9%
other ae 7.4%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
nausea 29.1%
NCT02014740 · Phase 4 · registry result, not featured evidence
nausea 31.4% (placebo 19.4%)
decreased in apetite 17.1% (placebo 11.1%)
diarrhea 11.4% (placebo 8.3%)
NCT01505673 · Phase 4 · registry result, not featured evidence
nausea 21.8%
diarrhoea 16.3%
decreased appetite 8.9%
NCT01907854 · Phase 4 · registry result, not featured evidence
nausea 21.8%
diarrhoea 12.4%
lipase increased 8.4%
NCT01973231 · Phase 4 · registry result, not featured evidence
nausea 14.8%
decreased appetite 10.9%
diarrhoea 8.2%
NCT02008682 · Phase 4 · registry result, not featured evidence
vomiting 5.3%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
gastrointestinal disorders 27.1% (placebo 5.7%)
general disorders and administration site conditions 2.9% (placebo 0%)
nervous system disorders 2.9% (placebo 2.9%)
NCT02889510 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 18.4%
diabetic retinopathy 7.8%
lipase increased 7.5%
NCT03172494 · Phase 3 · registry result, not featured evidence
decreased appetite 14.4%
diarrhoea 14.4%
lipase increased 12.2%
NCT03172494 · Phase 3 · registry result, not featured evidence
nausea 37.2% (placebo 2.7%)
diarrhea 17.9% (placebo 17.3%)
allergic reaction to liraglutide 1.3% (placebo 0%)
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 12.6%
lipase increased 12%
diabetic retinopathy 11.6%
NCT03175120 · Phase 3 · registry result, not featured evidence
headache 11.5%
nasopharyngitis 11.3%
diarrhoea 7.7%
NCT02501161 · Phase 3 · registry result, not featured evidence
nausea 26.2% (placebo 6%)
decreased appetite 9.4% (placebo 0%)
diarrhoea 9.4% (placebo 3%)
NCT02964247 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 38.5%
constipation 9.8%
diabetic retinopathy 6.2%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 34.4%
constipation 13.9%
diarrhoea 8.8%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 20%
diabetic retinopathy 16.2%
diarrhoea 14.3%
NCT02911948 · Phase 3 · registry result, not featured evidence
headache 8.6%
viral upper respiratory tract infection 7.7%
lipase increased 5.7%
NCT02773368 · Phase 3 · registry result, not featured evidence
nausea 11.1%
influenza 7.1%
diarrhoea 6.3%
NCT02420262 · Phase 3 · registry result, not featured evidence
nausea 5.2%
nasopharyngitis 4.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
nasopharyngitis 6.2%
nausea 5.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
headache 12.5% (placebo 12.5%)
asympomatic hyppglycaemia 6.3% (placebo 0%)
nausea 6.3% (placebo 0%)
NCT01937598 · Phase 3 · registry result, not featured evidence
nausea 9.4%
diarrhoea 7.2%
vomiting 5%
NCT01952145 · Phase 3 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 32 weeks versus 52 weeks.
  5. eThe reported result categories differ.
  6. fAssessment timepoints differ: 26 weeks versus 28 weeks.
  7. gTrial phases differ: Phase 3 versus Phase 4.
  8. hThe assessment timepoint is not available for both results.
  9. iAssessment timepoints differ: 84 weeks versus 156 weeks.
  10. jPopulation comparability has not been reviewed for 44 of these studies.
  11. kPopulation comparability has not been reviewed for 32 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

dulaglutide

Microvascular Composite 22.2% (n=4949) vs 25.1% (n=4952) placebo
event count · % of participants
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 1099 Participants as posted
HF Hospitalization or Urgent Visit 4.3% (n=4949) vs 4.6% (n=4952) placebo
event count · % of participants
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 213 Participants as posted
Unstable Angina Hospitalization 1.8% (n=4949) vs 1.6% (n=4952) placebo
event count · % of participants
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 88 Participants as posted
HbA1c Less Than or Equal to 6.5 51.1% (n=178) vs 24% (n=179) Insulin Glargine @ 26wk
responder rate · % of participants
HbA1c <=6.5%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 71.3% (n=178) vs 45.8% (n=179) Insulin Glargine @ 26wk
responder rate · % of participants
HbA1c <7%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
FBG -34.3 vs -37.8 Insulin Glargine mg @ 26wk
absolute change · mg
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
Weight -4.7 kg @ 36wk4.5 mg
absolute change · kg
No placebo or comparator arm
NCT03495102 · Phase 3
show 4 more results
-4 kg @ 36wk3 mg
NCT03495102 · Phase 3
-3.1 kg @ 36wk1.5 mg
NCT03495102 · Phase 3
-0.5 kg @ 52wk1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
-0.2 kg @ 52wk0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7% 71.48% (n=526) @ 36wk4.5 mg
responder rate · % of participants
No placebo or comparator arm
NCT03495102 · Phase 3
show 2 more results
64.68% (n=521) @ 36wk3 mg
NCT03495102 · Phase 3
56.98% (n=523) @ 36wk1.5 mg
NCT03495102 · Phase 3
Fasting Serum Glucose Change mg/dL -52.3 mg @ 36wk4.5 mg
absolute change · mg
No placebo or comparator arm
NCT03495102 · Phase 3
show 4 more results
-47.9 mg @ 36wk3 mg
NCT03495102 · Phase 3
-44.2 mg @ 36wk1.5 mg
NCT03495102 · Phase 3
-42.4 mg @ 52wk1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
-33.1 mg @ 52wk0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 8 78.3% (n=152) vs 75.3% (n=182) Insulin Glargine @ 26wk1.5 mg
responder rate · % of participants
NCT01621178 · Phase 3
show 3 more results
69.1% (n=152) vs 70.3% (n=182) Insulin Glargine @ 52wk1.5 mg
NCT01621178 · Phase 3
72.6% (n=164) vs 75.3% (n=182) Insulin Glargine @ 26wk0.75 mg
NCT01621178 · Phase 3
69.5% (n=164) vs 70.3% (n=182) Insulin Glargine @ 52wk0.75 mg
NCT01621178 · Phase 3
SMBG 8-point Change mg/dL -33.7 vs -37.6 Insulin Glargine mg @ 26wk1.5 mg
absolute change · mg
NCT01621178 · Phase 3
show 1 more result
-31.7 vs -37.6 Insulin Glargine mg @ 26wk0.75 mg
NCT01621178 · Phase 3
Fasting Glucose Change mg/dL 23.1 vs -19.1 Insulin Glargine mg @ 26wk1.5 mg
absolute change · mg
NCT01621178 · Phase 3
show 2 more results
17.7 vs -19.1 Insulin Glargine mg @ 26wk0.75 mg
NCT01621178 · Phase 3
-44.63 vs -27.9 placebo mg @ 28wk
NCT02152371 · Phase 3 · registry result, not featured evidence · combination

+ 53 further endpoints in the CSV export.

Liraglutide (Victoza)

MACE Broad 20.3% (n=4668) vs 22.7% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
All-cause Mortality 8.2% (n=4668) vs 9.6% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
Microvascular Composite 7.6% (n=4668) vs 8.9% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
BMI SDS -0.254 vs -0.208 placebo score @ 26wk1.8 mg
absolute change · score
NCT01541215 · Phase 3
show 1 more result
-0.361 vs -0.166 placebo score @ 52wk1.8 mg
NCT01541215 · Phase 3
HbA1c Less Than 7% 48.2% (n=56) vs 30.8% (n=52) placebo @ 52wk1.8 mg
event count · % of participants
NCT01541215 · Phase 3 · converted to % from 27 Participants as posted
show 8 more results
79.8% (n=341) vs 49.7% (n=167) Insulin Degludec @ 26wk*
Yes
NCT03172494 · Phase 3 · registry result, not featured evidence · converted to % from 272 Participants as posted
53% (n=151) vs 49.7% (n=167) Insulin Degludec @ 26wk*
Yes
NCT03172494 · Phase 3 · registry result, not featured evidence · converted to % from 80 Participants as posted
52.2% (n=289) vs 16.7% (n=138) Insulin Degludec @ 26wk*
Yes
NCT03175120 · Phase 3 · registry result, not featured evidence · converted to % from 151 Participants as posted
89.1% (n=275) vs 69.7% (n=271) Insulin Degludec @ 52wk*
Yes
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 245 Participants as posted
76.2% (n=273) vs 69.7% (n=271) Insulin Degludec @ 52wk*
Yes
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 208 Participants as posted
71.4% (n=105) vs 21.9% (n=105) Insulin Degludec @ 26wk*
Yes
NCT02911948 · Phase 3 · registry result, not featured evidence · converted to % from 75 Participants as posted
79.5% (n=210) vs 68.6% (n=210) IGlar @ 26wk*
Yes
NCT02773368 · Phase 3 · registry result, not featured evidence · converted to % from 167 Participants as posted
66% (n=238) vs 67% (n=233) IGlar + IAsp @ 26wk*
Yes
NCT02420262 · Phase 3 · registry result, not featured evidence · converted to % from 157 Participants as posted
HbA1c Less Than or Equal to 6.5 47.5% (n=59) vs 32.8% (n=58) placebo @ 26wk1.8 mg
event count · % of participants
NCT01541215 · Phase 3 · converted to % from 28 Participants as posted
show 7 more results
44.6% (n=56) vs 25% (n=52) placebo @ 52wk*1.8 mg
Yes
NCT01541215 · Phase 3 · converted to % from 25 Participants as posted
58.9% (n=341) vs 28.7% (n=167) Insulin Degludec @ 26wk*
Yes
NCT03172494 · Phase 3 · registry result, not featured evidence · converted to % from 201 Participants as posted
27.2% (n=151) vs 28.7% (n=167) Insulin Degludec @ 26wk*
Yes
NCT03172494 · Phase 3 · registry result, not featured evidence · converted to % from 41 Participants as posted
33.2% (n=289) vs 7.2% (n=138) Insulin Degludec @ 26wk*
Yes
NCT03175120 · Phase 3 · registry result, not featured evidence · converted to % from 96 Participants as posted
54.3% (n=105) vs 8.6% (n=105) Insulin Degludec @ 26wk*
Yes
NCT02911948 · Phase 3 · registry result, not featured evidence · converted to % from 57 Participants as posted
70% (n=210) vs 47.6% (n=210) IGlar @ 26wk*
Yes
NCT02773368 · Phase 3 · registry result, not featured evidence · converted to % from 147 Participants as posted
49.6% (n=238) vs 44.6% (n=233) IGlar + IAsp @ 26wk*
Yes
NCT02420262 · Phase 3 · registry result, not featured evidence · converted to % from 118 Participants as posted
HbA1c Less Than 7 Without Hypoglycemia 52.5% (n=59) vs 36.2% (n=58) placebo @ 26wk1.8 mg
event count · % of participants
NCT01541215 · Phase 3 · converted to % from 31 Participants as posted
show 3 more results
39.3% (n=56) vs 30.8% (n=52) placebo @ 52wk*1.8 mg
Yes
NCT01541215 · Phase 3 · converted to % from 22 Participants as posted
44.7% (n=76) vs 33% (n=88) Glargine @ 26wk*
NCT01919489 · Phase 4 · registry result, not featured evidence · combination · converted to % from 34 Participants as posted
48.2% (n=83) vs 33% (n=94) Glargine @ 12wk*
NCT01919489 · Phase 4 · registry result, not featured evidence · combination · converted to % from 40 Participants as posted
HbA1c Less Than 7 5 72.9% (n=59) vs 50% (n=58) placebo @ 26wk1.8 mg
event count · % of participants
NCT01541215 · Phase 3 · converted to % from 43 Participants as posted
show 1 more result
64.3% (n=56) vs 44.2% (n=52) placebo @ 52wk*1.8 mg
Yes
NCT01541215 · Phase 3 · converted to % from 36 Participants as posted
SMBG 7-point -2.384 vs 0.198 placebo mmol/L @ 26wk1.8 mg
absolute change · mmol/L
NCT01541215 · Phase 3
show 2 more results
-2.309 vs -0.748 placebo mmol/L @ 52wk1.8 mg
NCT01541215 · Phase 3
-2.25 vs -1.36 Sitagliptin mmol/L @ 26wk
NCT02008682 · Phase 4 · registry result, not featured evidence
PPG Excursion -0.428 vs -0.362 placebo mmol/L @ 26wk1.8 mg
absolute change · mmol/L
NCT01541215 · Phase 3
show 8 more results
-0.747 vs -0.397 placebo mmol/L @ 52wk1.8 mg
NCT01541215 · Phase 3
-0.2 vs 0.09 Insulin Degludec mmol/L @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
-0.54 vs 0.09 Insulin Degludec mmol/L @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
-0.28 vs 0.2 Insulin Glargine mmol/L @ 26wk
NCT02501161 · Phase 3 · registry result, not featured evidence
-0.47 vs 0.12 Insulin Glargine mmol/L @ 104wk
NCT02501161 · Phase 3 · registry result, not featured evidence
-0.74 vs -0.27 Insulin Degludec mmol/L @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-1.01 vs -0.27 Insulin Degludec mmol/L @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-0.76 vs 0.7 Insulin Degludec mmol/L @ 26wk
NCT02911948 · Phase 3 · registry result, not featured evidence
HbA1c 7.13% (n=136) vs 7.68% (n=137) Glargine @ 26wk
absolute value · percentage points
HbA1C at 6 months post-intervention
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without Weight Gain 33% (n=996) vs 23.5% (n=995) Oral Antidiabetic Drug @ 104wk1.8 mg
event count · % of participants
NCT02730377 · Phase 4 · registry result, not featured evidence · converted to % from 329 Participants as posted
show 8 more results
41% (n=78) vs 23.3% (n=90) Glargine @ 26wk*
NCT01919489 · Phase 4 · registry result, not featured evidence · combination · converted to % from 32 Participants as posted
40.7% (n=361) vs 19% (n=179) Insulin Degludec @ 26wk*
Yes
NCT03172494 · Phase 3 · registry result, not featured evidence · converted to % from 147 Participants as posted
41.1% (n=180) vs 19% (n=179) Insulin Degludec @ 26wk*
Yes
NCT03172494 · Phase 3 · registry result, not featured evidence · converted to % from 74 Participants as posted
32.5% (n=302) vs 4.6% (n=151) Insulin Degludec @ 26wk*
Yes
NCT03175120 · Phase 3 · registry result, not featured evidence · converted to % from 98 Participants as posted
16% (n=275) vs 8.1% (n=271) Insulin Degludec @ 52wk*
Yes
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 44 Participants as posted
52% (n=273) vs 8.1% (n=271) Insulin Degludec @ 52wk*
Yes
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 142 Participants as posted
47.6% (n=105) vs 8.6% (n=105) Insulin Degludec @ 26wk*
Yes
NCT02911948 · Phase 3 · registry result, not featured evidence · converted to % from 50 Participants as posted
43.3% (n=210) vs 18.1% (n=210) IGlar @ 26wk*
Yes
NCT02773368 · Phase 3 · registry result, not featured evidence · converted to % from 91 Participants as posted

+ 117 further endpoints in the CSV export.

Atherosclerotic Cardiovascular Disease

Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline

dulaglutide · Trulicity

Marketed by Eli Lilly

Approved in Atherosclerotic Cardiovascular Diseasepeptide
Reliable signal

NCT01394952 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).

Next expected readout: December 2030 · NCT07282041 (registry estimate)

Reported efficacy

Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 (met)

Result source: NCT01394952

Liraglutide (Victoza)

Marketed by Novo Nordisk

Approved in Atherosclerotic Cardiovascular Diseasepeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdulaglutideLiraglutide (Victoza)
LDL-C, % change—Trial running · NCT07282041—Not reported
Non-HDL-C, % change—Trial running · NCT07282041—Not reported
ApoB, % change—Trial running · NCT07282041—Not reported
Lp(a), % change—Trial running · NCT07282041—Not reported
3-point MACE (% with event)—Trial running · NCT0728204113% vs 14.9%−1.9 vs placebowk 260 · n 4668NCT01179048

LDL-C, % change

dulaglutide
—Trial running · NCT07282041
Liraglutide (Victoza)
—Not reported

Non-HDL-C, % change

dulaglutide
—Trial running · NCT07282041
Liraglutide (Victoza)
—Not reported

ApoB, % change

dulaglutide
—Trial running · NCT07282041
Liraglutide (Victoza)
—Not reported

Lp(a), % change

dulaglutide
—Trial running · NCT07282041
Liraglutide (Victoza)
—Not reported

3-point MACE (% with event)

dulaglutide
—Trial running · NCT07282041
Liraglutide (Victoza)
13% vs 14.9%−1.9 vs placebowk 260 · n 4668NCT01179048
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

dulaglutide
Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 NCT01394952 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. dulaglutide: 0 of 4 rows · Liraglutide (Victoza): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLiraglutide (Victoza)
Dropout rate
3%a
NCT01179048 · Phase 3
show 3 more results
0%
NCT03260881 · Phase 4 · registry result, not featured evidence
10%
NCT04881110 · Phase 4 · registry result, not featured evidence
0%
NCT03010683 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01179048 · Phase 3
show 3 more results
—
NCT03260881 · Phase 4 · registry result, not featured evidence
—
NCT04881110 · Phase 4 · registry result, not featured evidence
—
NCT03010683 · Phase na · registry result, not featured evidence
Serious AEs
49.7%a
NCT01179048 · Phase 3
show 3 more results
0%
NCT03260881 · Phase 4 · registry result, not featured evidence
0%
NCT04881110 · Phase 4 · registry result, not featured evidence
0%
NCT03010683 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
nausea 11.1% (placebo 2.8%)
diarrhoea 5.7% (placebo 2.2%)
NCT01179048 · Phase 3
show 1 more result
abdominal distention 31.6%
nausea 31.6%
NCT03260881 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Liraglutide (Victoza)

MACE 3-point Composite 13% (n=4668) vs 14.9% (n=4672) placebo @ 260wk
event count · % of participants
NCT01179048 · Phase 3
MACE Broad 20.3% (n=4668) vs 22.7% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
All-cause Mortality 8.2% (n=4668) vs 9.6% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
Microvascular Composite 7.6% (n=4668) vs 8.9% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
Tcpo2 54.2 vs 43.4 placebo mmHg @ 26wk
absolute change · mmHg
NCT04881110 · Phase 4 · registry result, not featured evidence
HbA1c 6.7% (n=27) vs 6.8% (n=28) placebo @ 26wk
absolute change · percentage points
NCT04881110 · Phase 4 · registry result, not featured evidence
Fasting Glucose Change mg/dL 6.58 vs 6.49 placebo mmol/L @ 26wk
absolute change · mmol/L
NCT04881110 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 118.5 mg/dL as posted
BMI 28.7 vs 27.7 placebo kg @ 26wk
absolute change · kg
NCT04881110 · Phase 4 · registry result, not featured evidence
Waist Circumference Change 108.9 vs 104.1 placebo cm @ 26wk
absolute change · cm
NCT04881110 · Phase 4 · registry result, not featured evidence
CRP Change mg/dL 0.5 vs 0.8 placebo mg/dL @ 26wk
absolute change · mg/dL
NCT04881110 · Phase 4 · registry result, not featured evidence
Serum Creatinine Change mg/dL 1 vs 0.8 placebo mg/dL @ 26wk
absolute change · mg/dL
NCT04881110 · Phase 4 · registry result, not featured evidence
ABI 0.9 vs 1 placebo ratio @ 26wk
ratio to baseline · ratio
NCT04881110 · Phase 4 · registry result, not featured evidence

+ 1 further endpoint in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dulaglutide's landscape · Liraglutide (Victoza)'s landscape